Wegovy pill (semaglutide)
Wegovy pill is a daily tablet product containing semaglutide, made by Novo Nordisk. Its approved use in the U.S. is weight management.
Educational information. This page does not give dosing instructions or tell you what to take. The current label and a prescriber decide that.
What Wegovy pill is
- Generic name
- Semaglutide
- Maker
- Novo Nordisk
- Form
- Daily tablet
- U.S. approved use
- Weight management
- First U.S. approval
- 2025
How it differs from related products
The Wegovy pill contains the same drug as the Wegovy injection, but as a daily tablet instead of a weekly injection. It is also a different product from Rybelsus, which contains oral semaglutide approved for type 2 diabetes.
| Product | Form | U.S. approved use | Status |
|---|---|---|---|
| Wegovy | Weekly injection | Weight management | FDA-approved for weight management |
| Wegovy HD | Weekly injection (higher strength) | Weight management | FDA-approved for weight management |
| Wegovy pill (this page) | Daily tablet | Weight management | FDA-approved for weight management |
| Ozempic | Weekly injection | Type 2 diabetes | FDA-approved, but not for obesity |
| Rybelsus | Daily tablet | Type 2 diabetes | FDA-approved, but not for obesity |
What it is approved for
- Weight reduction in adults with obesity, or overweight plus a weight-related condition
- Reducing the risk of major cardiovascular events in adults with established heart disease and obesity or overweight
How it is taken
Per the label, the tablet is taken once a day in the morning on an empty stomach, with plain water (up to 4 ounces), and swallowed whole. The label says to wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.
What the trials found
These are group averages from published trials of this product's weight-management use, in adults without diabetes.
OASIS 4
Average change in body weight. Every bar uses one scale, 0 to 25 percent.
- People studied
- 307 adults with obesity, or overweight plus at least one obesity-related complication, without diabetes (205 oral semaglutide, 102 placebo)
- Length
- 64 weeks
- Compared with
- Placebo once daily, with lifestyle support in both groups
- What was measured
- Estimated average change in body weight at week 64
- Analysis approach
- Not stated in the abstract. Check the full paper.
- Other results
- More people on oral semaglutide reached weight reductions of at least 5%, 10%, 15% and 20%. A trade-press report cites 16.6% vs 2.7% for time on treatment. That is a different analysis from the abstract's figures, so check which one a number comes from.
- Safety
- Gastrointestinal adverse events: 74.0% with oral semaglutide vs 42.2% with placebo.
- Limits
- A smaller trial than the injectable semaglutide program. Funded by the manufacturer.
Sources: Wharton S 2025, FDA approves Wegovy pill, the first oral GLP-1 to treat obesity
Safety
Warnings, side effects and open questions for semaglutide are on the semaglutide page. The official label is the controlling source.
Compiled from public information: FDA-approved labels, manufacturer websites, ClinicalTrials.gov and published journal articles. Sources are listed at the bottom of this page.
Related
Semaglutide
The generic page: how it works, safety, and what is still unknown.
Wegovy
Wegovy and Ozempic both contain semaglutide as a weekly injection, but they are separate products with different approved uses.
Wegovy HD
Wegovy HD is a higher-strength version of the Wegovy weekly injection.
Ozempic
Ozempic contains semaglutide, the same drug as Wegovy, and is also a weekly injection.
Rybelsus
Rybelsus is oral semaglutide approved for type 2 diabetes.
Sources
- Wegovy (semaglutide) injection and tablets: prescribing information Novo Nordisk, on DailyMed (U.S. National Library of Medicine). Label version 6/2026. One label covers both the injection and the tablets. Official FDA label on DailyMed
- FDA approves Novo Nordisk's Wegovy pill Pharmaceutical Commerce, December 2025. Trade press, secondary source
- FDA approves Wegovy pill, the first oral GLP-1 to treat obesity Healio. Trade press. Reports on-treatment OASIS 4 figures and how the pill is taken. Not the label. Trade press, secondary source
- DailyMed: current FDA drug labels U.S. National Library of Medicine. Regulator
- Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4) Wharton S, et al. N Engl J Med. 2025;393(11):1077-1087. PMID 40934115. Funding: Novo Nordisk. Journal article